Abstracts Archive - Page 590 of 2607 - ACR Meeting Abstracts

Abstract Number: 1609 • ACR Convergence 2022
Comorbidity Clusters in Ankylosing Spondylitis and Their Association with Disease Activity and Functional Impairment: Data from the PSOAS Cohort
Paras Karmacharya¹, Cynthia Crowson², Ryan Lennon³, Dilli Poudel⁴, John Davis³, Alexis Ogdie⁵, Jean Liew⁶, Michael Ward⁷, Mariko Ishimori⁸, Michael Weisman⁹, Matthew Brown¹⁰, Mohammad Rahbar¹¹, Mark Hwang¹², John Reveille¹³ and Lianne Gensler¹⁴, ¹Vanderbilt University, Nashville, TN, ²Mayo Clinic, Eyota, MN, ³Mayo Clinic, Rochester, MN, ⁴Indiana Regional Medical Center, Indiana, PA, ⁵Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁶Boston University, Boston, MA, ⁷National Institutes of Health, Rockville, MD, ⁸Cedars-Sinai Health System, Los Angeles, CA, ⁹Adjunct Professor of Medicine, Stanford University; Distinguished Professor of Medicine Emeritus, David Geffen School of Medicine at UCLA, Los Angeles, CA, ¹⁰Genomics England, London, United Kingdom, ¹¹University of Texas Health Science Center at Houston, Houston, TX, ¹²McGovern Medical School at the University of Texas Health Science Center at Houston, Houston, TX, ¹³University of Texas McGovern Medical School, Houston, TX, ¹⁴Department of Medicine, Division of Rheumatology, University of California San Francisco, San Francisco, CA
Background/Purpose: Comorbidities occur more frequently in patients with ankylosing spondylitis (AS) than in the general population and are associated with higher morbidity and mortality. Some…
Abstract Number: 1599 • ACR Convergence 2022
Bimekizumab Treatment in Patients with Active Psoriatic Arthritis and Inadequate Response to Tumor Necrosis Factor Inhibitors: 16-Week Efficacy and Safety from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
Joseph Merola¹, Robert Landewé², Iain B McInnes³, Philip J Mease⁴, Christopher Ritchlin⁵, Yoshiya Tanaka⁶, Akihiko Asahina⁷, Frank Behrens⁸, Dafna Gladman⁹, Laure Gossec¹⁰, Richard Warren¹¹, Barbara Ink¹², Deepak Assudani¹², Rajan Bajracharya¹², Jason Coarse¹³ and Laura Coates¹⁴, ¹Harvard Medical School, Brigham and Women's Hospital, Boston, MA, ²Amsterdam University Medical Center, Meerssen, Netherlands, ³Institute of Infection, Immunity and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, Scotland, United Kingdom, ⁴Swedish Medical Center/Providence St. Joseph Health, Seattle, WA, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶University of Occupational and Environmental Health, Kitakyusyu Fukuoka, Japan, ⁷Department of Dermatology, The Jikei University School of Medicine, Tokyo, Japan, ⁸Rheumatology University Hospital & Fraunhofer Institute Translational Medicine and Pharmacology, Goethe-University Frankfurt, Frankfurt Am Main, Germany, ⁹Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada, ¹⁰Sorbonne Université, Paris, France, ¹¹The University of Manchester, Manchester, United Kingdom, ¹²UCB Pharma, Slough, United Kingdom, ¹³UCB Pharma, Raleigh, NC, USA, Raleigh, NC, ¹⁴Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK, Oxford, England, United Kingdom
Background/Purpose: Bimekizumab (BKZ) is a monoclonal IgG1 antibody that selectively inhibits IL-17F in addition to IL-17A. The phase 3 BE COMPLETE study assessed the efficacy…
Abstract Number: 1607 • ACR Convergence 2022
Machine Learning Identifies Biomarker of Non-Response to Methotrexate in Rheumatoid Arthritis
Vincent Bouget¹, Julien Duquesne¹, Paul-Henry Cournède², Bruno Fautrel³, Francis Guillemin⁴, Pascal de Jong⁵, Judith Heutz⁶, Marloes Verstappen⁷, Annette van der Helm-van Mil⁸, Xavier Mariette⁹ and Samuel Bitoun¹⁰, ¹Scienta Lab, Paris, France, ²Paris-Saclay University - CentraleSupelec, Paris, France, ³Sorbonne University Paris, France and Pierre Louis Institute of Epidemiology and Public Health, Paris, France, Paris, France, ⁴Université de Lorraine, APEMAC, Vandoeuvre-les-nancy, France, ⁵ErasmusMC, Hendrik Ido Ambacht, Netherlands, ⁶Erasmus Medical Center, Rotterdam, Netherlands, ⁷Leiden University Medical Center, Leiden, Netherlands, ⁸Leiden University Medical Center, Erasmus Medical Center, Leiden, Netherlands, ⁹Paris-Saclay University, Rueil Malmaison, Ile-de-France, France, ¹⁰Paris-Saclay University, Paris, France
Background/Purpose: Methotrexate (MTX) is the first line treatment for rheumatoid arthritis (RA). Unfortunately, 30% to 40% of RA patients do not respond to MTX with…
Abstract Number: 1620 • ACR Convergence 2022
Probability-based Diagnostic Algorithm in Suspected Giant Cell Arteritis: A Prospective, Multicentre Validity Data from HAS GCA Study
Alwin Sebastian¹, alessandro tomelleri², PIERLUIGI MACCHIONI³, Giulia Klinowski³, Carlo Salvarani⁴, Abdul Kayani⁵, Mohammad Tariq⁵, Diana Prieto-Peña⁶, Edoardo Conticini⁷, Muhammad Khurshid⁸, Sue Inness⁹, Jo Jackson⁹, Kornelis van der Geest¹⁰ and Bhaskar Dasgupta⁵, ¹University Hospital Limerick, Dooradoyle, Ireland, ²IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milano, Italy, ³IRCCS-S.Maria Nuova, Reggio Emilia, Italy, ⁴Azienda USL -IRCCS di Reggio Emilia and Università di Modena e Reggio Emilia, Reggio Emilia, Reggio Emilia, Italy, ⁵Mid and South Essex University Hospital Groups, Southend, United Kingdom, ⁶Research Group on Genetic Epidemiology and Atherosclerosis in Systemic Diseases and in Metabolic Bone Diseases of the Musculoskeletal System, IDIVAL; and Department of Rheumatology, Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁷Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy, ⁸University Hospital Dorset, NHS foundation trust, UK, Poole, United Kingdom, ⁹University of Essex, School of Sport, Rehabilitation and Exercise science, Colchester, United Kingdom, ¹⁰University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: The presentation of new-onset giant cell arteritis (GCA) is highly variable. It is vital to make a secure diagnosis to minimise the risk for…
Abstract Number: 1614 • ACR Convergence 2022
Females with Non-Radiographic but Not with Radiographic Axial Spondyloarthritis Are Less Likely to Achieve Inactive Disease State Than Males: Results from a Multicountry Prospective Observational Study
Denis Poddubnyy¹, Joachim Sieper², Servet Akar³, Santiago Muñoz-Fernández⁴, Hildrun Haibel², Torsten Diekhoff⁵, Mikhail Protopopov⁶, Elisabeth Altmaier⁷, Fabiana Ganz⁸ and Robert Inman⁹, ¹Department of Gastroenterology, Infectious Diseases and Rheumatology, Charité – Universitätsmedizin Berlin, Berlin, Germany, ²Charité - Universitätsmedizin, Berlin, Berlin, Germany, ³Izmir Katip Celebi University School of Medicine, Izmir, Turkey, ⁴Servicio de Reumatología, Hospital Universitario Infanta Sofía, Universidad Europea, Madrid, Spain, ⁵Department of Radiology, Charité-Universitätsmedizin Berlin, Berlin, Germany, ⁶Charité Universitätsmedizin Berlin, Berlin, Germany, ⁷GKM Gesellschaft für Therapieforschung mbH, Munich, Germany, ⁸AbbVie, Inc., Luzern, Switzerland, ⁹University Health Network, Toronto, ON, Canada
Background/Purpose: Emerging evidence suggests that men and women experience axial spondyloarthritis (axSpA) differently. Some studies suggested that the probability of treatment response was lower in…
Abstract Number: 1616 • ACR Convergence 2022
Drug Use and Pregnancy Outcomes in Pregnant Women with Systemic Vasculitis: A Nation Wide Cohort Study
Camille Mettler¹, Nathanaël Beeker², Mathis Collier², Veronique Le Guern³, Benjamin Terrier⁴ and Laurent Chouchana⁵, ¹Department of Internal Medicine, National Referral Center for Rare Systemic and Autoimmune Diseases, Cochin Hospital, Paris, France, ²Unité de Recherche clinique, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France, ³Hôpital Cochin, Paris, France, ⁴National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France, ⁵Pharmacology department, Centre Régional de Pharmacovigilance, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France
Background/Purpose: Women of childbearing age are rarely affected by systemic vasculitis (SV), explaining the lack of solid data regarding pregnancy in these patients. The objective…
Abstract Number: 1612 • ACR Convergence 2022
Prediction of Psoriatic Arthritis Tool (PRESTO): Development and Performance of a New Scoring System for Psoriatic Arthritis Risk
Lihi Eder¹, Ker-Ai Lee², Vinod Chandran³, Jessica Widdifield⁴, Aaron Drucker⁴, Christopher Ritchlin⁵, Cheryl F Rosen⁴, Richard Cook² and Dafna Gladman⁶, ¹Women’s College Research Institute, Department of Medicine, University of Toronto, Toronto, ON, Canada, ²University of Waterloo, Waterloo, ON, Canada, ³Departments of Medicine and Laboratory Medicine and Pathobiology, University of Toronto/ Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Toronto, ON, Canada, ⁴University of Toronto, Toronto, ON, Canada, ⁵Allergy, Immunology and Rheumatology Division, University of Rochester Medical School, Canandaigua, NY, ⁶Toronto Western Hospital, Schroeder Arthritis Institute, Toronto, ON, Canada
Background/Purpose: A simple, scalable tool that identifies psoriasis patients at high risk for developing PsA could improve early detection and facilitate early intervention. Our overall…
Abstract Number: 1623 • ACR Convergence 2022
Combined Single-Cell, Bulk RNA Sequencing and Proteomics Analysis Reveals New Candidate Targets Involved in Myocardial Fibrogenesis
Ievgeniia Kocherova¹, Elena Pachera², Daria Nurzynska³, Franca Di Meglio³, Oliver Distler⁴, Przemysław Błyszczuk² and Gabriela Kania², ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Schlieren, Switzerland, ²Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland, ³Department of Public Health, University of Naples "Federico II", Naples, Italy, ⁴Department of Rheumatology, University Hospital Zurich, University of Zurich, Zürich, Switzerland
Background/Purpose: Inflammatory dilated cardiomyopathy (iDCM) often leads to heart failure (HF), which is the main cause of cardiac mortality in patients with systemic autoimmune diseases.…
Abstract Number: 1625 • ACR Convergence 2022
Single Cell and Spatial Transcriptomics Identifies Pathogenic Drivers of Sjogren’s Disease in Humans
Blake Warner¹, Thomas Pranzatelli², Paola Perez², Daniel Martin², Shyh-Ing Jang², Kalie Dominick², Eiko Yamada², Kevin Byrd³, Quinn Easter⁴, A. Darise Farris⁵, Christopher Lessard⁵, Amanda Oliver⁶, Raquel Bartolome-Casado⁶, Zohreh Khavandgar¹, Sarthak Gupta⁷, Sarah Teichmann⁶, Alan Baer⁸ and John Chiorini², ¹National Institutes of Health, Bethesda, MD, ²NIDCR, Bethesda, MD, ³American Dental Association, Scientific Research Institute, Gaithersburg, MD, ⁴American Dental Association, Gaithersburg, MD, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶Wellcome Sanger Institute, Cambridgeshire, United Kingdom, ⁷National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁸Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Sjogren's Disease(SjD) is a systemic autoimmune disease characterized by exocrine dysfunction. The pathogenesis is incompletely understood, but involves gene-environment interactions leading to infiltration of…
Abstract Number: 1622 • ACR Convergence 2022
TNF Receptor 1 Drives Murine Pulmonary Arterial Hypertension and Is Characterized by Loss of Capillary Endothelial Cells and Pericytes, Smooth Muscle Cell Proliferation, and Alterations in Fibroblast Phenotype
Stacey Duemmel¹, Marc Nuzzo¹, Soumyaroop Bhattacharya¹, Qingfu Xu¹, Amy Mohan¹ and Benjamin Korman², ¹URMC, Rochester, NY, ²University of Rochester, Rochester, NY
Background/Purpose: We previously demonstrated that TNF-transgenic (TNF-Tg) mice have findings consistent with connective-tissue disease associated pulmonary arterial hypertension (CTD-PAH), and that this pathology is mediated…
Abstract Number: 1624 • ACR Convergence 2022
Blocking IL-1, IL-33 and IL-36 Signaling with the Anti-IL1RAP Antibody mCAN10 Ameliorates Inflammation and Fibrosis in Preclinical Models of Systemic Sclerosis
Caitriona Grönberg¹, Sara Rattik¹, Meik Kunz², Thoung Trinh-Minh³, Cuong Tran-Manh³, Xiang Zhou³, Petter Skoog¹, David Liberg¹ and Jörg Distler³, ¹Cantargia AB, LUND, Sweden, ²Friedrich-Alexander University (FAU) Erlangen-Nuremberg, Erlangen, Germany, ³Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany
Background/Purpose: The IL-1 receptor accessory protein (IL1RAP) is a co-receptor required for signaling through the IL-1, IL-33, and IL-36 receptors. IL1RAP-dependent signaling has been implicated…
Abstract Number: 1119 • ACR Convergence 2022
Investigating Macrophage Heterogeneity in the Esophagus and Lungs of SSc Patients
Hadijat Makinde¹, Carla Cuda¹, Miranda Gurra¹, Mary Carns², Kathleen Aren², Gaurav Gadhvi¹, Salina Dominguez¹, Jane Dematte³, Darren Brenner⁴, John Pandolfino⁵, G. R. Scott Budinger⁴, Deborah Winter⁶ and Harris Perlman¹, ¹Northwestern University, Chicago, IL, ²Northwestern University Division of Rheumatology, Chicago, IL, ³Northwestern University, Elmhurst, IL, ⁴Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵Northwestern University, Feinberg School of Medicine, Wilmette, IL, ⁶Northwestern University, Skokie, IL
Background/Purpose: Our group has made important contributions to an emerging understanding of monocytes and macrophages as central to SSc pathogenesis. There are numerous studies that…
Abstract Number: 1566 • ACR Convergence 2022
Outcome of Vascular Involvement of Behçet Syndrome Treated with Infliximab: A Retrospective Cohort Study
gulen Hatemi¹, Nur Beyza Tukek², Sinem Nihal Esatoglu¹, Yesim Ozguler³, Sitki Safa Taflan², Melike Melikoglu¹, Serdal Ugurlu⁴, Izzet Fresko¹, Zekayi Kutlubay⁵, Sebahattin Yurdakul¹, Hasan Yazici⁶ and Vedat Hamuryudan⁷, ¹Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Istanbul, Turkey, ³Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, New York, NY, ⁴Istanbul University-Cerrahpaşa, Istanbul, Turkey, ⁵Istanbul University-Cerrahpaşa, Cerrahpasa Medical Faculty, Department of Dermatology, Istanbul, Turkey, ⁶Letter to Editor Rheumatology, Istanbul, Turkey, ⁷Istanbul University-Cerrahpaşa, Cerrahpaşa Medical School, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey
Background/Purpose: Vascular involvement is an important cause of morbidity and mortality in patients with Behçet syndrome (BS). We aimed to survey the efficacy and safety…
Abstract Number: 1516 • ACR Convergence 2022
How Disease Activity Can Affect Workability in Spondyloarthropaties: A Monocentric Cohort Analysis
Federico Fattorini¹, Cosimo Cigolini², Gabriele Marchetti³, Andrea Delle Sedie⁴, Linda Carli⁵ and Marta Mosca⁵, ¹Rheumatology Unit, University of Pisa, Pisa, Italy, ²Rheumatology Unit, University of Pisa, Pisa, Toscana, Italy, ³University of Pisa, Pisa, Toscana, Italy, ⁴University of Pisa, Pisa, Pisa, Italy, ⁵Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, PISA, Italy
Background/Purpose: Spondyloarthropathies (SpA) may compromise the working ability (WA) of patients, often affected by the disease during their productive life. The Work Productivity and Activity…
Abstract Number: 1372 • ACR Convergence 2022
Telemedicine Use in the Assessment of Juvenile Dermatomyositis and Polymyositis: A Survey of Caregivers and Patients
Stacey Tarvin¹, Y. Ingrid Goh², Nicole Taylor³, Bianca Lang⁴, Marietta De Guzman⁵, Julie Fuller⁶, Kristin Houghton⁷, Susan Kim⁸, Vanessa Carbone⁹, Kathryn Cook¹⁰, Tanya Slater⁹, Angela Robinson¹¹, Liza McCann¹², Charalampia Papadopoulou¹³, Clarissa Pilkington¹⁴, Phoebe Rushe¹⁵ and Peter Blier¹⁶, ¹Riley Hospital for Children at Indiana University Health, Indianapolis, IN, ²Division of Rheumatology, The Hospital for Sick Children; Child Health Evaluative Services, SickKids Research Institute, Toronto, ON, Canada, ³University of Indianapolis, Indianapolis, IN, ⁴Dalhousie University - Halifax, Halifax, NS, Canada, ⁵Baylor College of Medicine/ Texas Children's Hospital, Houston, TX, ⁶UT Southwestern, Frisco, TX, ⁷University of British Columbia - Vancouver, Vancouver, BC, Canada, ⁸UCSF Benioff Children's Hospital, San Francisco, CA, ⁹The Hospital for Sick Children, Toronto, ON, Canada, ¹⁰Akron Children's Hospital, Copley, OH, ¹¹Cleveland Clinic, Cleveland, OH, ¹²Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom, ¹³UCL Institute of Child Health, and Great Ormond Street Hospital NHS Foundation Trust, Section Head Infection, Immunology, and Rheumatology, London, United Kingdom, ¹⁴Great Ormond Street Hospital, London, United Kingdom, ¹⁵Royal Liverpool University Hospital, Liverpool, United Kingdom, ¹⁶Retired, Amherst, MA
Background/Purpose: Care of patients with juvenile myositis (JM) involves complex assessments performed by highly trained specialists. Restrictions surrounding the COVID-19 pandemic resulted in many patients…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].